ArticleJournal of virology2020
Labyrinthopeptins Exert Broad-Spectrum Antiviral Activity through Lipid-Binding-Mediated Virolysis.
Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Filamentous multiscale characterization of the cultivation of Actinomadura namibiensis pellets for model-based prediction of labyrinthopeptin A1 biosynthesis.Microbial cell factories · 2026Article
- Gut-protective metabolic phenotype for diarrhoeal remission caused by an environmental probiotic thermophile.Microbiome · 2026Article
- Plant-Derived Carotenoid Lutein Demonstrates Multifunctional Antiviral Activity against Influenza A VirusJournal of microbiology and biotechnology · 2025Article
- Membrane-Targeting Antivirals.International journal of molecular sciences · 2025Review
- The untapped potential of actinobacterial lanthipeptides as therapeutic agents.Molecular biology reports · 2023Review
- Discovery of phosphorylated lantibiotics with proimmune activity that regulate the oral microbiome.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Discovery and biosynthesis of tricyclic copper-binding ribosomal peptides containing histidine-to-butyrine crosslinks.Nature communications · 2023Article
- Natural Products and Derivatives as PotentialViruses · 2023Review
- Synthesis of Ribosomally Synthesized and Post-Translationally Modified Peptides Containing C-C Cross-Links.Journal of natural products · 2022Review
- Mechanism of Action of Ribosomally Synthesized and Post-Translationally Modified Peptides.Chemical reviews · 2022Review
- Natural products as Zika antivirals.Medicinal research reviews · 2022Review
- In-Depth Characterization of Zika Virus Inhibitors Using Cell-Based Electrical Impedance.Microbiology spectrum · 2022Article
- Contemporary exploitation of natural products for arthropod-borne pathogen transmission-blocking interventions.Parasites & vectors · 2022Review
- Precision Postbiotics and Mental Health: the Management of Post-COVID-19 Complications.Probiotics and antimicrobial proteins · 2022Review
- Pathogenicity and virulence of West Nile virus revisited eight decades after its first isolation.Virulence · 2021Article
- Understanding the Mechanism of Action of NAI-112, a Lanthipeptide with Potent Antinociceptive Activity.Molecules (Basel, Switzerland) · 2021Article
- Are the Organoid Models an Invaluable Contribution to ZIKA Virus Research?Pathogens (Basel, Switzerland) · 2021Review
- Therapeutic Application of Lantibiotics and Other Lanthipeptides: Old and New Findings.Applied and environmental microbiology · 2021Review
- Chikungunya and Zika Viruses: Co-Circulation and the Interplay between Viral Proteins and Host Factors.Pathogens (Basel, Switzerland) · 2021Review
- Mining and Biosynthesis of Bioactive Lanthipeptides From Microorganisms.Frontiers in bioengineering and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To counteract the serious health threat posed by known and novel viral pathogens, drugs that target a variety of viruses through a common mechanism have attracted recent attention due to their potential in treating (re)emerging infections, for which direct-acting antivirals are not available. We found that labyrinthopeptins A1 and A2, the prototype congeners of carbacyclic lanthipeptides, inhibit the proliferation of diverse enveloped viruses, including dengue virus, Zika virus, West Nile virus, hepatitis C virus, chikungunya virus, Kaposi's sarcoma-associated herpesvirus, cytomegalovirus, and herpes simplex virus, in the low micromolar to nanomolar range. Mechanistic studies on viral particles revealed that labyrinthopeptins induce a virolytic effect through binding to the viral membrane lipid phosphatidylethanolamine (PE). These effects are enhanced by a combined equimolar application of both labyrinthopeptins, and a clear synergism was observed across a concentration range corresponding to 10% to 90% inhibitory concentrations of the compounds. Time-resolved experiments with large unilamellar vesicles (LUVs) reveal that membrane lipid raft compositions (phosphatidylcholine [PC]/PE/cholesterol/sphingomyelin at 17:10:33:40) are particularly sensitive to labyrinthopeptins in comparison to PC/PE (90:10) LUVs, even though the overall PE amount remains constant. Labyrinthopeptins exhibited low cytotoxicity and had favorable pharmacokinetic properties in mice (half-life [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.